SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- diabetes
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (238)9/8/2008 1:57:41 PM
From: keokalani'nui   of 278
 
content.nejm.org

Here's the answer, from the paper:

In the continuous-monitoring group, the use of sensors was greater among patients who were 25 years of age or older than in the other two age groups (P<0.001). The use of sensors was consistently high during the 26-week period among patients in the oldest age group but declined over time in the other two age groups (Figure 3). Excluding the three patients who dropped out, only one patient who was 25 years of age or older, seven who were 15 to 24 years of age, and two who were 8 to 14 years of age discontinued continuous glucose monitoring before completing the 26-week visit. At least 6.0 days of sensor use per week was the average for 83% of patients who were 25 years of age or older, 30% who were 15 to 24 years of age, and 50% who were 8 to 14 years of age. Sensor use was not associated with the baseline glycated hemoglobin level (Spearman's correlation coefficients, 0.08, –0.02, and 0.03 in the three groups, respectively).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News